Skip to main content
. 2013 Dec;15(12):1314–1329. doi: 10.1593/neo.131718

Figure 5.

Figure 5

GNE-617 decreases FDG uptake in PC3 tumor xenografts, which is reversed by NA co-treatment. (A–C) PC3 tumor xenografts grown in the hind flank were treated (Rx) orally with vehicle (control), GNE-617, NA, or the combination of NA and GNE-617 for 4 days at the doses indicated. Animals were dosed with 18-FDG tracer as described in Materials and Methods section. Changes in tumor volume (A), FDG uptake (B, MRGlucMAX), and mean blood glucose levels (C) were measured as described in Materials and Methods section. (D) Maximum image projections of FDG-PET uptake in tumor tissue from representative animals at day 0 (pre-treatment baseline) and day 4 across the four treatment groups as shown. Arrows designate location of tumors. Colorimetric scale denotes degree of FDG-PET uptake with upper limits defined in the yellow range. Comparisons between treated groups and vehicle control were performed by Dunnett method: *P < .05, ***P < .0005.